In preclinical studies of dasatinib in combination with another TKI, radotinib, AML cell death was induced in a c-Kit-dependent mechanism, demonstrating its potential as a therapy in AML (Fig. 3).157 In a phase Ib/IIa study, dasatinib was given to newly diagnosed CBF-AML patients following standard induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.